Precision Gene Editing Strategies with CRISPR-Cas9 for Advancing Cancer Immunotherapy and Alzheimer's Disease

Abstract

Precision medicine approaches such as gene editing via clustered regularly interspaced short palindromic repeat (CRISPR) and their associated protein (Cas-9) are revolutionizing treatment strategies for complex diseases such as Alzheimer and cancer. In this review, we explore the application of CRISPR-Cas9 in advancing therapies for these conditions, as well as its potential in targeting senescent cells. Since the risk of Alzheimer’s disease is strongly associated with genetic mutations and variations, the use of gene editing technologies to rectify these genetic errors by modifying disease-associated proteins becomes relevant. For cancer, to enhance immunotherapy approaches, modification of immune cells have been utilized to improve their anti-tumor efficacy. Additionally, the review also investigates the role of CRISPR-Cas9 in targeting senescent cells, which are implicated in both aging-related disorders and cancer progression. While challenges remain in introducing delivery methods and specificity, CRISPR-Cas9 represents a significant advancement in developing targeted, personalized treatments for these challenging health issues.